Evidence map›Paper›PMID 38897290›Full record

ArticleMolecular & cellular proteomics : MCP2024

A Targeted LC-MRM

Nicolas Drouin, Hyung L Elfrink, Stefan A Boers, Sam van Hugten, Els Wessels, Jutte J C de Vries, Geert H Groeneveld, Paul Miggiels, Bart Van Puyvelde, Maarten Dhaenens and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Advances in COVID-19 and Cancer Research.Journal of clinical medicine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Nicolas DrouinMetabolomics and Analytics Centre, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. Electronic address: n.f.p.drouin@lacdr.leidenuniv.nl.
Hyung L ElfrinkMetabolomics and Analytics Centre, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Stefan A BoersLeiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.
Sam van HugtenLeiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.
Els WesselsLeiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.
Jutte J C de VriesLeiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.
Geert H GroeneveldLeiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands; Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Paul MiggielsMetabolomics and Analytics Centre, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Bart Van PuyveldeProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.
Maarten DhaenensProGenTomics, Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium.
Andries E BuddingInbiome, Amsterdam, The Netherlands.
Leonie RanEurofins, Amsterdam, The Netherlands.
Roy MasiusEurofins, Amsterdam, The Netherlands.
Zoltan TakatsFaculty of Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom.
Arjen BoogaerdsDSM, Geleen, The Netherlands.
Markus BultersDSM, Geleen, The Netherlands.
Wouter MuurlinkTSE, Haarlem, The Netherlands.
Paul OostvogelRegional Laboratory, Municipal Health Service (GGD) Amsterdam, Amsterdam, The Netherlands.
Amy C HarmsMetabolomics and Analytics Centre, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
Mariken van der LubbenRegional Laboratory, Municipal Health Service (GGD) Amsterdam, Amsterdam, The Netherlands.
Thomas HankemeierMetabolomics and Analytics Centre, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. Electronic address: hankemeier@lacdr.leidenuniv.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since its first appearance, severe acute respiratory syndrome coronavirus 2 quickly spread around the world and the lack of adequate PCR testing capacities, especially during the early pandemic, led the scientific community to explore new approaches such as mass spectrometry (MS). We developed a proteomics workflow to target several tryptic peptides of the nucleocapsid protein. A highly selective multiple reaction monitoring-cubed (MRM

Indexed as

COVID-19NasopharynxProteomicsSARS-CoV-2Chromatography, LiquidCoronavirus Nucleocapsid ProteinsHumansMass SpectrometryPhosphoproteinsSensitivity and SpecificityCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2Phosphoproteinsclinical validationdiagnostic testhigh-throughput proteomicsmass spectrometryMRM(3)SARS-CoV-2

Identifiers

PMID38897290
PMCPMC11284538

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.